Hot Investor Mandate 3: Asia-Based Pharma Opens US Office to Make Early Stage Equity Investments in Novel Platform Technologies

13 Jul

A pharmaceutical enterprise headquartered in Beijing, China has set up a biotech subsidiary in the USA and is actively seeking cutting-edge life science technologies around the world. The firm makes equity investments of US$2-10 million in Seed to Series B stage companies, while later stages up to pre-IPO may also be considered. For overseas deals, the firm prefers to co-invest with top-tier lead investors. The firm is looking for opportunities across the globe.

The firm is looking for technologies that are a strategic fit with its portfolio across biopharmaceuticals, medical devices, healthcare IT and healthcare services. The firm is most interested in innovative platform technology in small molecule or biologic therapeutics targeting large markets in China, including aging population, oncology, diabetes, women and children’s health. The firm considers early-stage companies from seed to Series B.

The firm seeks experienced management teams backed by strong, reputable VC firms. The firm typically requests board representation post-investment. The firm prefers to retain China rights, but this is not a requirement for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: